Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) EBT: 2013-2024

Historic EBT for vTv Therapeutics (VTVT) over the last 12 years, with Dec 2024 value amounting to -$22.6 million.

  • vTv Therapeutics' EBT fell 77.14% to -$10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.4 million, marking a year-over-year decrease of 25.52%. This contributed to the annual value of -$22.6 million for FY2024, which is 12.94% up from last year.
  • As of FY2024, vTv Therapeutics' EBT stood at -$22.6 million, which was up 12.94% from -$26.0 million recorded in FY2023.
  • vTv Therapeutics' EBT's 5-year high stood at -$12.8 million during FY2020, with a 5-year trough of -$26.0 million in FY2023.
  • Over the past 3 years, vTv Therapeutics' median EBT value was -$24.9 million (recorded in 2022), while the average stood at -$24.5 million.
  • In the last 5 years, vTv Therapeutics' EBT surged by 41.38% in 2020 and then plummeted by 41.20% in 2022.
  • Yearly analysis of 5 years shows vTv Therapeutics' EBT stood at -$12.8 million in 2020, then tumbled by 37.60% to -$17.6 million in 2021, then slumped by 41.20% to -$24.9 million in 2022, then decreased by 4.39% to -$26.0 million in 2023, then climbed by 12.94% to -$22.6 million in 2024.